TY - JOUR T1 - Serial interval of novel coronavirus (COVID-19) infections JF - medRxiv DO - 10.1101/2020.02.03.20019497 SP - 2020.02.03.20019497 AU - Hiroshi Nishiura AU - Natalie M. Linton AU - Andrei R. Akhmetzhanov Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/02/17/2020.02.03.20019497.abstract N2 - Objective To estimate the serial interval of novel coronavirus (COVID-19) from information on 28 infector-infectee pairs.Methods We collected dates of illness onset for primary cases (infectors) and secondary cases (infectees) from published research articles and case investigation reports. We subjectively ranked the credibility of the data and performed analyses on both the full dataset (n=28) and a subset of pairs with highest certainty in reporting (n=18). In addition, we adjusting for right truncation of the data as the epidemic is still in its growth phase.Results Accounting for right truncation and analyzing all pairs, we estimated the median serial interval at 4.0 days (95% credible interval [CrI]: 3.1, 4.9). Limiting our data to only the most certain pairs, the median serial interval was estimated at 4.6 days (95% CrI: 3.5, 5.9).Conclusions The serial interval of COVID-19 is shorter than its median incubation period. This suggests that a substantial proportion of secondary transmission may occur prior to illness onset. The COVID-19 serial interval is also shorter than the serial interval of severe acute respiratory syndrome (SARS), indicating that calculations made using the SARS serial interval may introduce bias.Highlights- The serial interval of novel coronavirus (COVID-19) infections was estimated from a total of 28 infector-infectee pairs.- The median serial interval is shorter than the median incubation period, suggesting a substantial proportion of pre-symptomatic transmission.- A short serial interval makes it difficult to trace contacts due to the rapid turnover of case generations.Competing Interest StatementThe authors have declared no competing interest.Funding StatementH.N. received funding support from Japan Agency for Medical Research and Development [grant number: JP18fk0108050] the Japan Society for the Promotion of Science (JSPS) Grants-in-Aid for Scientific Research (KAKENHI in Japanese abbreviation) grant nos. 17H04701, 17H05808, 18H04895 and 19H01074, and the Japan Science and Technology Agency (JST) Core Research for Evolutional Science and Technology (CREST) program [grant number: JPMJCR1413]. NML receive graduate study scholarships from the Ministry of Education, Culture, Sports, Science and Technology, Japan.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data can be obtained from Supplementary Table. ER -